Should I Buy EBS? EBS 2026 Analysis

Should You Buy Emergent BioSolutions Inc (EBS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

10.920

1 Day change

3.61%

52 Week Range

14.060

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action is weak (bearish MACD expansion) and the stock is sitting just above near-term support, suggesting downside risk outweighs upside for an impatient entry.
Options positioning looks bullish (very low put/call ratios), but the underlying trend + heavy insider selling makes that sentiment unreliable as a standalone buy signal.
With earnings coming on 2026-02-25 (after hours) and recent YoY revenue/EPS declines, the nearer-term risk skew is unfavorable; avoid/new money should stay out until trend improves.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.0738) and negatively expanding → bearish momentum is increasing.
RSI: RSI(6) at 39.38 → weak/near-oversold but not signaling a confirmed reversal.
Moving averages: converging MAs → no clear trend reversal confirmation; more consistent with consolidation in a weak tape.
Key levels: Price 11.44 is just above S1 (11.381); if S1 fails, next support S2 ~11.075. Upside needs reclaim of Pivot 11.878, then R1 12.375.
Pattern-based projection: similar-pattern stats imply modest positive drift over 1W/1M, but near-term (next day) slightly negative.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Very low put/call ratios (OI and volume) → options market skew is bullish/call-heavy.
Volatility: 30D IV 104.38 vs historical vol 59.81 → options are pricing very large moves; IV percentile 65.74 indicates elevated relative pricing.
Liquidity note: Today’s option volume is small (42 contracts total; puts 2, calls 40), so sentiment signals can be noisy.
Setup implication: If trading short-term, this is more consistent with a high-volatility “bounce attempt” environment than a clean trend-following long entry.

Technical Summary

Sell

Buy

Positive Catalysts

- Options market skew is strongly call-heavy (bullish positioning).
- Price is near support (S1 ~11.381), which can mechanically attract dip-buying/bounce attempts.
- Gross margin improved YoY (62.74%, +7.67% YoY), suggesting some operational efficiency despite revenue decline.
- Upcoming earnings (QDEC 2025 on 2026-02-25 after hours) can act as a catalyst if results/guide surprise positively.

Neutral/Negative Catalysts

- Bearish momentum: MACD histogram negative and expanding lower.
- Insider activity: insiders are selling, and selling amount increased ~207.62% over the last month.
- Fundamentals (latest reported quarter): revenue, net income, and EPS all declined sharply YoY (weak growth trend).
- No supportive recent news flow in the past week (no obvious positive catalyst to reverse momentum now).
- Elevated implied volatility implies the market expects large moves; without a clear edge, this increases adverse-move risk into earnings.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: 231.1M, down -21.34% YoY → top-line contraction.
Net income: 51.2M, down -55.40% YoY → profitability declined significantly.
EPS: 0.91, down -55.83% YoY → earnings power deteriorated.
Gross margin: 62.74%, up +7.67% YoY → margin improvement is a bright spot, but not enough to offset the broad YoY declines.
Next known event: QDEC 2025 earnings on 2026-02-25 (after hours).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

The analyst updates shown in the dataset appear to reference a different company (Erste Group Bank), so they are not usable for EBS sentiment.
No valid, recent EBS-specific analyst rating/price-target change data was provided here.
Wall Street-style pros/cons view from available data: Pros = improved gross margin + potential event catalyst at earnings; Cons = shrinking revenue/earnings + bearish technical momentum + notable insider selling.

1 Analyst Rating

Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 15 USD with a low forecast of 15 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 10.540

Low

Averages

High

Current: 10.540

Low

Averages

High

JPMorgan

NULL -> Overweight

maintain

AI Analysis

2025-12-02

Reason

JPMorgan

Price Target

AI Analysis

2025-12-02

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Erste Group Bank to EUR 107 from EUR 102 and keeps an Overweight rating on the shares.

Barclays

Equal Weight -> Overweight

upgrade

€106

2025-12-02

Reason

Barclays

Price Target

€106

2025-12-02

upgrade

Equal Weight -> Overweight

Reason

Barclays upgraded Erste Group Bank to Overweight from Equal Weight with a EUR 106 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EBS

Unlock Now

EBS Should I Buy

EBS Should I Buy

Should You Buy Emergent BioSolutions Inc (EBS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch